Clinical Trials Browser

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06536049 2026-02-19

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Recruiting

38 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03479268 2025-11-26

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

18 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT04446962 2025-09-25

LOC-R01

Phase 1/2 Active not recruiting

118 enrolled

CNSLymphoid

Lymphoma, Neurologic Manifestations, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Phase 1 Completed

34 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03939182 2025-04-25

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Phase 1 Completed

15 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03440567 2025-03-26

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Phase 1 Completed

16 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03129828 2024-12-13

ImbruVeRCHOP

Phase 1/2 Completed

38 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02692248 2024-10-10

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Phase 2 Completed

64 enrolled 17 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03136497 2024-09-23

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 1 Terminated

10 enrolled 14 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03399513 2024-01-05

R-CHOEP-brut

Phase 2 Completed

40 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02874404 2023-10-05

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Completed

13 enrolled 10 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02756247 2022-10-10

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Phase 1 Completed

37 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03949062 2021-02-17

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Phase 2 Unknown

30 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04025593 2020-11-19

Biomarker Guided Treatment in DLBCL

Phase 2 Unknown

128 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02950220 2019-07-30

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1 Completed

2 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02955628 2017-02-14

RICE-ibrutinib in Relapsed DLBCL

Phase 2 Unknown

34 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

LOC-R01

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

ImbruVeRCHOP

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

R-CHOEP-brut

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Biomarker Guided Treatment in DLBCL

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

RICE-ibrutinib in Relapsed DLBCL